A 25-year-old man with refractory schizophrenia and clozapine-induced myocarditis diagnosed by non-invasive cardiovascular magnetic resonance

Abstract

Patient: Male, 25-year-old Final Diagnosis: Clozapine-induced myocarditis Symptoms: Elevated troponin • fever • leukocytosis • somnolence • tachycardia Medication: — Clinical Procedure: Cardiovascular magnetic resonance • electrocardiogram • transthoracic echocardiogram Specialty: Cardiology • General and Internal Medicine Objective: Background: Case Report: Conclusions: Rare disease Clozapine, a second-generation antipsychotic, is often prescribed for refractory schizophrenia; however, it can cause life-threatening adverse events including agranulocytosis and myocarditis. Making the diagnosis of clo-zapine-induced myocarditis can be challenging given the non-specific presentation as well as risk involved in obtaining an endomyocardial biopsy. As clozapine-induced myocarditis carries a mortality risk of up to 30%, timely recognition, diagnosis, and management are vital. This report presents a case of clozapine-induced myo-carditis in a 25-year-old man with refractory schizophrenia who was diagnosed using non-invasive imaging with cardiovascular magnetic resonance (CMR). A 25-year-old man with refractory schizophrenia was admitted with severe psychotic symptoms and started on a rapid titration of clozapine. During his hospitalization he developed somnolence, fever, and tachycardia with leukocytosis, elevated inflammatory markers, and cardiac biomarkers concerning for clozapine-induced myocarditis. Alternative etiologies were ruled out and CMR was used to confirm the diagnosis. The patient’s symptoms resolved following discontinuation of clozapine and initiation of supportive therapies. Clozapine-induced myocarditis is challenging to diagnose due to a lack of consensus on diagnostic criteria, reli-ance on voluntary reporting, and non-specific presentation. This report highlights that myocarditis can be associated with clozapine pharmacotherapy in patients with schizophrenia and demonstrates the value of diagnosis using non-invasive CMR. Additional studies are needed to understand the mechanism of clozapine-induced myocarditis and how clozapine titration may affect risk.